Clik here to view.
Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI®...
CASTRES, France Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the...
View ArticleClik here to view.
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan...
BOTHELL, Wash. Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry of...
View ArticleClik here to view.
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial,...
View ArticleClik here to view.
PeptiDream Announces Drug Discovery and Development Agreement with Santen...
KAWASAKI, Japan PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a broad-based multi-target discovery and...
View ArticleClik here to view.
Konica Minolta Launches Dedicated Precision Medicine Business in Japan
TOKYO Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) today announced the launch of Konica Minolta Precision Medicine Japan, Inc. (“KMPMJ”) which will start operations on...
View ArticleClik here to view.
武田收到CHMP肯定意见，推荐ALUNBRIG® (brigatinib)用于治疗既往用过克唑替尼的ALK+非小细胞肺癌患者
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)已采纳一项肯定意见，推荐全面核准ALUNBRIG®...
View ArticleClik here to view.
AVITA Medical Announces Presentation of RECELL® System Effectiveness and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the results from two U.S. pivotal clinical trials...
View ArticleClik here to view.
PerkinElmer and DBT- ICT Inaugurate “explorer™ G3 Project”– an Advanced...
MUMBAI, India PerkinElmer, Inc., a global leader committed to innovating for a healthier world, collaborated with Institute of Chemical Technology (ICT) to open “explorerTM G3 Project,” an advanced...
View ArticleClik here to view.
Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO™...
CAMBRIDGE, Mass. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japan’s Pharmaceuticals...
View ArticleClik here to view.
F351 Liver Fibrosis Trial Shows Positive Efficacy
TOKYO GNI Group Ltd., (“GNI Group”; TOKYO: 2160) has received a recommendation from the independent data monitoring committee (IDMC) reviewing the F351 drug candidate’s Phase II liver fibrosis trial...
View ArticleClik here to view.
武田薬品、クリゾチニブによる前治療歴のあるALK陽性非小細胞肺がん患者の治療薬としてALUNBRIG®（ブリガチニブ）を推奨するCHMPの肯定的見解を取得
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ）– 武田薬品工業株式会社（TSE: 4502）は本日、欧州医薬品庁（EMA）の医薬品評価委員会（CHMP）...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical...
View ArticleClik here to view.
Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global...
SOUTH SAN FRANCISCO, Calif. & SHANGHAI Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, and Zai...
View ArticleClik here to view.
Visioneering Technologies Selects Corneal Lens Corporation NZ and Contact...
ATLANTA Visioneering Technologies, Inc. (ASX: VTI), an innovative US-based medical device company dedicated to developing advanced products that improve vision, today announced that it has signed an...
View ArticleClik here to view.
武田薬品、進行性ALK陽性NSCLCに対するファーストライン治療でALUNBRIG®（ブリガチニブ）がクリゾチニブと比較して病状進行ないし死亡のリスクを5...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、第3相ALTA-1L試験（ALK in Lung Cancer Trial of BrigAtinib in 1st...
View ArticleClik here to view.
武田呈报的ALTA-1L试验阳性数据显示，ALUNBRIG® (brigatinib)用于晚期ALK+...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布，3期ALTA-1L（ALK in Lung Cancer Trial of BrigAtinib in 1st...
View ArticleClik here to view.
CANbridge Pharmaceutical Submits New Drug Application for NERLYNX®...
BEIJING CANbridge Pharmaceutical Inc., a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it has filed a New Drug Application (NDA) to China’s...
View ArticleClik here to view.
CORRECTING and REPLACING CANbridge Pharmaceutical Submits New Drug...
BEIJING Second sentence of first paragraph of release dated October 2, 2018, should read: The NMPA has accepted the NDA application. (instead of The NMPA has accepted the IND application.). The...
View ArticleClik here to view.
Axcelead Drug Discovery Partners とERS Genomics、CRISPR /...
藤沢市 （ビジネスワイヤ）– Axcelead Drug Discovery Partners 株式会社社（代表取締役社長：池浦義典、本社：神奈川県藤沢市、以下「アクセリード」）とERS Genomics Limited（代表取締役社長：エリック・ローズ、本社：アイルランド ダブリン、以下「ERS」）は、ERSが管理するCRISPR /...
View ArticleClik here to view.
Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9...
FUJISAWA, Japan & DUBLIN Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a...
View Article